

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form for
File Information Unit
Crystal Plaza Three, Room 1100
2001 South Clark Place
Arlington, VA
Telephone: (703) 305-2738

RECEIVED
FEB 25 2004
File Information Unit

In re Application of

Reiter et al.

Application Number

09/636801

File

8-10-00

Page No.

[Signature]

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. 2003/0165504, page, _____ line _____

United States Patent Number _____, column _____, line _____ or _____

WIPO Pub. No. _____, page _____, line _____

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
- the pending application as originally filed.

[Signature]

Signature

J. LUCUDINE

Typed or printed name

Registration Number, if applicable

703-413-0600

Telephone Number

2-25-04

Date

RECEIVED

Approved by

FEB 25 2004

File Information Unit

Best Available Copy



US 20030165504A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2003/0165504 A1****Retter et al.**(43) **Pub. Date: Sep. 4, 2003**(54) **COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAN CANCER**(76) **Inventors:** Marc W. Retter, Carnation, WA (US);
Gary R. Fanger, Mill Creek, WA (US)**Correspondence Address:**
SEED INTELLECTUAL PROPERTY LAW
GROUP PLLC
701 FIFTH AVE
SUITE 6300
SEATTLE, WA 98104-7092 (US)(21) **Appl. No.: 09/827,271**(22) **Filed: Apr. 4, 2001****Related U.S. Application Data**(63) **Continuation-in-part of application No. 09/667,857, filed on Sep. 29, 2000, which is a continuation-in-part of application No. 09/636,801, filed on Aug. 10, 2000, now abandoned, which is a continuation-in-part of application No. 09/617,747, filed on Jul. 17, 2000, now abandoned, which is a continuation-in-part of application No. 09/404,879, filed on Sep. 24, 1999, now Pat. No. 6,468,546, which is a continuation-in-****part of application No. 09/338,933, filed on Jun. 23, 1999, now Pat. No. 6,488,931, which is a continuation-in-part of application No. 09/216,003, filed on Dec. 17, 1998, and which is a continuation-in-part of application No. 09/215,681, filed on Dec. 17, 1998, now Pat. No. 6,528,253.****Publication Classification**(51) **Int. Cl.⁷ A61K 39/395; C12N 9/00;**
C07K 16/40(52) **U.S. Cl. 424/146.1; 435/183; 530/388.26**(57) **ABSTRACT**

Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer.